-0% Off

Calquence (Acalabrutinib)


Calquence is a cutting-edge prescription medication designed to provide targeted treatment for specific types of cancer, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).



Calquence is a cutting-edge prescription medication designed to provide targeted treatment for specific types of cancer, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This oral medication is formulated to combat cancer cells by inhibiting the action of Bruton tyrosine kinase (BTK), a protein that plays a crucial role in the growth of cancerous B cells.

Additional information


• Follow your healthcare provider's instructions precisely for taking CALQUENCE.
• Do not alter your dose or discontinue CALQUENCE without your healthcare provider's guidance.
• If you experience certain side effects, your healthcare provider may adjust your dose, temporarily pause, or halt CALQUENCE.
• Take CALQUENCE two times daily, spaced approximately 12 hours apart.
• CALQUENCE can be consumed with or without food.
• Swallow CALQUENCE tablets whole with water; do not chew, crush, dissolve, or cut them.
• If you skip a dose of CALQUENCE, take it as soon as you remember. If over 3 hours past your usual dosing time, skip it and take the next dose at the scheduled time. Do not take an extra dose to compensate for a missed one.

Side Effects

Side Effects
CALQUENCE may lead to severe side effects, including:
• Occurrence of severe infections, which can be fatal. If you're at a higher infection risk, your healthcare provider might prescribe specific medications. Contact your healthcare provider immediately if you display infection signs such as fever, chills, or flu-like symptoms.
• Potential for severe bleeding (hemorrhage) during CALQUENCE treatment. Taking blood thinners may raise your bleeding risk. Notify your healthcare provider if you experience signs of bleeding, like dark or tar-like stools, pink or brown urine, uncontrollable bleeding, blood in vomit or vomit resembling coffee grounds, coughing up blood or blood clots, dizziness, confusion, persistent headache, or unusual bruising or skin discoloration.
• Decreased blood cell counts, including white blood cells, platelets, and red blood cells. While these reductions are common with CALQUENCE, they can also be severe. Regular blood tests are necessary to monitor your blood counts during CALQUENCE treatment.
• Development of secondary primary cancers. Some individuals have developed new cancers like skin or organ cancers while taking CALQUENCE. Regular skin cancer assessments are recommended during treatment, and sun protection is advised when outdoors.
• Heart rhythm disturbances (atrial fibrillation and atrial flutter) have been observed in CALQUENCE-treated patients. If you experience symptoms such as rapid or irregular heartbeat, dizziness, faintness, chest discomfort, or shortness of breath, inform your healthcare provider.
The most frequent side effects of CALQUENCE encompass headache, diarrhea, muscle and joint pain, upper respiratory tract infections, and bruising.


-Store Calquence at room temperature, away from excess heat and moisture. Keep the medication in its original container and make sure it's tightly closed. Keep it in a place that is inaccessible to children and pets at all times.

Safety Information

Safety Information
Before initiating CALQUENCE, disclose all your medical conditions to your healthcare provider, including whether you:
• Recently underwent surgery or intend to undergo one. CALQUENCE may need to be paused for planned medical, surgical, or dental procedures.
• Experience bleeding issues.
• Have a medical history involving irregularities in heart rhythm.
• Are currently dealing with an infection.
• Have or had liver disorders, including hepatitis B virus (HBV) infection.
• Are pregnant or have pregnancy plans? CALQUENCE could harm your unborn child and contribute to childbirth complications (dystocia).
o If you can conceive, a pregnancy test might be conducted before commencing CALQUENCE treatment.
o Females capable of pregnancy should utilize effective birth control during CALQUENCE therapy and for a week following the last dose.
• Are breastfeeding or have breastfeeding intentions? It's uncertain if CALQUENCE enters breast milk. Refrain from breastfeeding during CALQUENCE treatment and for two weeks after your final dose.
Inform your healthcare provider about all medications you're taking, whether prescription, over-the-counter, vitamins, or herbal supplements. Concurrent use of certain drugs may impact CALQUENCE's effectiveness and lead to adverse effects. Specifically, mention if you're taking blood thinners.


There are no reviews yet.

Be the first to review “Calquence (Acalabrutinib)”

Your email address will not be published. Required fields are marked *